A recent study suggested the activation of apelin/APJ signaling decreased efficacy in VEGF treatment, while bevacizumab decreased disease-free survival rates with increased expression of apelin in patients of ovarian cancer.
The priority review was based on results from the phase III PAOLA-1 trial comparing the addition of olaparib to bevacizumab vs the standard-of-care alone.
Largest analysis of data to date shows no link between use of talc powder and rate of ovarian cancer incidence
A study showed that first-line treatment for epithelial ovarian cancer using weekly dose-dense chemotherapy did not improve progression-free survival, compared with 3-weekly chemotherapy, in European women.
Patients recently diagnosed with ovarian cancer indicated that they would accept a moderately higher risk of complication and surgical mortality in exchange for higher overall survival.
The updated and expanded NCCN guidelines broaden the testing criteria, while clarifying who should be tested for genetic mutations.
Research suggests that oncogene S100A10 may play a definitive role in the progression of ovarian cancer and its expression levels may affect sensitivity to carboplatin.
Researchers compared primary high grade serous ovarian carcinoma tumors and their matched metastasis, showing evidence of separating the 2 sample types and potentially predicting patient survival.
Dr. Allison W. Kurian discusses a new breast cancer study that analyzed the mutations present in breast tumors, and about emerging targeted therapy options.
The approval comes one day after the FDA approved niraparib for the same subset of ovarian cancer.